Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 3/20 | 0.39 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | CCKBR | P32239 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 5/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724175 | 0.89 | HTT (0.42) | HTTSMN1; SMN2HRH2HRH1CCKBR | |
| SCHEMBL3722441 | 0.86 | HTT (0.44) | HTTSMN1; SMN2HRH2HRH1CCKBR | |
| SCHEMBL677001 | 0.85 | OXER1 (0.38) | PARP1 | |
| SCHEMBL3731938 | 0.84 | HTT (0.41) | HTTSMN1; SMN2HRH2HRH1CCKBR | |
| SCHEMBL3728130 | 0.83 | HTT (0.43) | HTTSMN1; SMN2HRH2HRH1CCKBR | |
| SCHEMBL674904 | 0.80 | HTT (0.49) | HTTSMN1; SMN2HRH1PARP1HRH3 | |
| SCHEMBL675862 | 0.80 | HTT (0.41) | HTTSMN1; SMN2HRH2HRH1CCKBR | |
| SCHEMBL675861 | 0.80 | HTT (0.41) | HTTSMN1; SMN2HRH2HRH1CCKBR | |
| SCHEMBL3724173 | 0.79 | HTT (0.43) | HTTSMN1; SMN2PARP1HRH3PDE3B | |
| SCHEMBL3723793 | 0.79 | PARP1 (0.43) | HTTSMN1; SMN2HRH2HRH1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | HTT 4100/4885SMN1; SMN2 3499/4885HRH2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.